Highlights
- •PDT using both ALA and EDTA-2Na showed bactericidal effect against PS.
- •EDTA-2Na inhibited to produce biofilm of PA.
- •PDT using both ALA and EDTA-2Na healed faster wound infected with PA than non-PDT.
Abstract
Background
Pseudomonas aeruginosa (PA) frequently develops antibiotic-resistant characteristics, which is clinically
problematic. The main reason behind the rise of antibiotic-resistant PA is the extensive
use of antibiotics. Therefore, a novel technique is needed to treat PA infections.
Photodynamic therapy (PDT) is thought to have the potential to be a non-antibiotic
treatment for infections. 5-Aminolevulinic acid (ALA), which works as a photosensitizer
after being metabolized into protoporphyrin IX (PpIX) in the heme synthetic pathway,
is used for PDT. Thus far, the in vivo effectiveness of PDT using ALA against PA is unknown.
Objective
In this study, we investigated PDT using ALA both in vitro and in vivo.
Methods and results
Although PDT with ALA alone did not show a bactericidal effect on PA, PDT with both
ALA and EDTA-2Na had a bactericidal effect in vitro. In in vivo experiments, wounds healed faster in PA-infected mice treated with PDT using both
EDTA-2Na and ALA compared to non-PDT.
Conclusion
These results suggest that PDT with EDTA-2Na and ALA is a potential novel treatment
option for PA-infected wounds.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Dermatological ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Alexander Fleming and the discovery of penicillin.Adv. Appl. Microbiol. 2001; 49: 163-184
- Antibiotic resistance and its cost: is it possible to reverse resistance?.Nature Rev. Microbiol. 2010; 8: 260-271
- A systematic review and meta-analysis of misuse of antibiotic therapies in the community.Int. J. Antimicrob. Agents. 2005; 26: 106-113
- Photodynamic therapy: a new antimicrobial approach to infectious disease?.Photochem. Photobiol. Sci. 2004; 3: 436-450
- Anti-microbial photodynamic therapy: useful in the future?.Lasers Med. Sci. 2007; 22: 83-91
- Photodynamic therapy using systemic administration of 5-aminolevulinic acid and a 410-nm wavelength light-emitting diode for methicillin-resistant Staphylococcus aureus-infected ulcers in mice.PLoS One. 2014; 9: e105173
- Photodynamic therapy for cancer.Nat. Rev. Cancer. 2003; 3: 380-387
- Antimicrobial photodynamic therapy: an overview.J. Indian Soc. Periodontol. 2011; 15: 323-327
- Antimicrobial strategies centered around reactive oxygen species–bactericidal antibiotics, photodynamic therapy, and beyond.FEMS Microbiol. Rev. 2013; 37: 955-989
- A review of progress in clinical photodynamic therapy.Technol. Cancer Res. Treat. 2005; 4: 283-293
- Recent advances in photodynamic diagnosis of gastric cancer using 5-aminolevulinic acid.World J. Gastroenterol. 2016; 22: 1289-1296
- Delta-aminolaevulinic acid-induced porphyrin synthesis and photodynamic inactivation of Escherichia coli B.J. Photochem. Photobiol. B Biol. 1999; 50: 8-17
- Efficacy of 5-aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes in human colon cancer cells.Oncol. Rep. 2013; 29: 911-916
- Photodynamic therapy for nonmelanoma skin cancers. Current review and update.Mol. Immunol. 2003; 39: 1133-1136
- Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives.Pharm. Res. 2000; 17: 1447-1455
- Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma.J. Eur. Acad. Dermatol. Venereol. 2001; 15: 550-554
- Photosensitized inactivation of microorganisms.Photochem. Photobiol. Sci. 2004; 3: 403-405
- Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans.J. Antimicrob. Chemother. 2011; 66: 1525-1532
- Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa.Antimicrob. Agents Chemother. 1995; 39: 1948-1953
- Mechanisms of antibiotic resistance in Pseudomonas aeruginosa.J. R. Soc. Med. 2002; 95: 22-26
- The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa.J. Med. Microbiol. 2006; 55: 1619-1629
- Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria.BMC Infect. Dis. 2005; 5: 24
- Burn patients infected with metallo-beta-lactamase-producing pseudomonas aeruginosa: multidrug-resistant strains.Arch. Trauma Res. 2014; 3: e18182
- Oxygen availability for porphyrin biosynthesis enzymes determines the production of protoporphyrin IX (PpIX) during hypoxia.PLoS One. 2015; 10: e0146026
- Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis.Mol. Microbiol. 1998; 28: 449-461
- Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts.Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 5405-5410
- Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response.J. Antimicrob. Chemother. 2013; 68: 177-183
- Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.Int. J. Antimicrob. Agents. 2015; 45: 161-167
- The influence of iron chelators on the accumulation of protoporphyrin IX in 5-aminolaevulinic acid-treated cells.Br. J. Cancer. 1996; 74: 688-697
- Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent.Med. Res. Rev. 2012; 32: 1292-1327
- Molecular basis of bacterial outer membrane permeability.Microbiol. Rev. 1985; 49: 1-32
- Studies on the mechanism of bacteria photosensitization by meso-substituted cationic porphyrins.J. Photochem. Photobiol. B Biol. 1996; 35: 149-157
- Transport of 5-aminolevulinic acid by the dipeptide permease in Salmonella typhimurium.J. Bacteriol. 1993; 175: 325-331
- Transport of intact porphyrin by HpuAB, the hemoglobin-haptoglobin utilization system of Neisseria meningitidis.J. Bacteriol. 1998; 180: 6043-6047
- Calcium-mediated modulation of Pseudomonas mendocina NR802 biofilm influences the phenanthrene degradation.Colloids Surf. B Biointerfaces. 2014; 114: 301-309
- Comparison of the efficacy of ALA-PDT using an excimer-dye laser (630 nm) and a metal-halide lamp (600 to 740 nm) for treatment of Bowen's disease.Photodermatol. Photoimmunol. Photomed. 2012; 28: 142-146
- 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.Cancer. 1997; 79: 2282-2308
- Photodynamic therapy against common bacteria causing wound and skin infections.Vet. J. 2012; 192: 374-377
- Effects on gram-negative and gram-positive bacteria mediated by 5-aminolevulinic Acid and 5-aminolevulinic acid derivatives.Antimicrob. Agents Chemother. 2008; 52: 1366-1373
- Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation.PLoS One. 2012; 7: e39823
- Photodynamic therapy induces an immune response against a bacterial pathogen.Expert Rev. Clin. Immunol. 2012; 8: 479-494
- Topical photodynamic treatment with poly-L-lysine-chlorin p6 conjugate improves wound healing by reducing hyperinflammatory response in Pseudomonas aeruginosa-infected wounds of mice.Lasers Med. Sci. 2013; 28: 465-471
Article info
Publication history
Published online: March 05, 2018
Accepted:
March 2,
2018
Received in revised form:
February 14,
2018
Received:
June 18,
2017
Identification
Copyright
© 2018 Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.
